Immune checkpoint inhibitors such as anti-PD-1 antibodies and anti-CTLA-4 antibodies, regulatory cytokines, and metabolic reprogramming targeting the tumor microenvironment work to reverse the exhausted T cell states, restore their functionality, and reactivate immune responses. The gene discussed is CTLA4; the disease is neoplasm.